Toripalimab and BCG for high-risk bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have high-risk or very high-risk non-muscle-invasive bladder cancer (NMIBC) that hasn't spread into the muscle layer of your bladder.
- You have not received BCG therapy or immune checkpoint inhibitors before.
- You are in good physical condition (fully active or able to do light work) and your blood counts, liver, and kidney function are adequate.
- You are not pregnant and are willing to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special type of tumor removal (ERBT) followed by BCG immunotherapy is better than standard treatment for medium- or high-risk non-muscle-invasive bladder cancer. It may help people whose bladder cancer has come back, has multiple tumors, or has a tumor larger than 1 cm.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests whether radiation therapy can help people whose bladder cancer (specifically carcinoma in situ) did not get better with BCG treatment and who are not having their bladder removed. It aims to offer a less invasive option for controlling the cancer.
This early-phase trial tests durvalumab given with an experimental bladder cancer vaccine to help stop or slow high-risk bladder cancer that did not respond to or cannot be treated with BCG. It also evaluates safety and how well the treatment works in this setting.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.